Blog

Lipid Surveyor™: Lipidomic Analysis Tool

Lipidomic Analysis

Streamlined, accurate, and accessible data analyses suites for lipidomic studies can powerfully accelerate your experiments. To fulfill data analysis and visualization needs, Metabolon’s offers the Lipid Surveyor tool, an innovative, online biomarker discovery and pathway mapping tool designed to visualize, analyze, and interpret lipidomic study results with a rich collection of capabilities. Lipid Surveyor allows investigators to simply and efficiently view studies performed with Metabolon, download data files, and build visual reports of results.

Define Your Lipidomics Study Parameters

Utilizing Lipid Surveyor, investigators can view their reports and define their experimental parameters for analyses. Investigators begin by configuring their report using the “Discovery” option and selecting “Biomarker Performance” to compare study groups, determine display formats, and set comparison parameters. Data can be further configured to include matrices for multiple sample types, calculate fold-changes or mean differences from control groups, as well as sort options ranging from standard order, magnitude of difference, and significance. Lipid Surveyor utilizes a simple click-and-go interface to allow users to quickly begin visualization of their results.

Visualize Your Lipidomics Results

After Discovery reports are configured, data visualization in Surveyor is intuitive and easily customizable. Depending on the parameters set by the investigator, a bar chart is displayed highlighting differences between groups across all metabolites detected along with a summary box displaying overall changes detected in your study, including the total number of metabolites detected and how many reached statistical significance. For instance, if an investigator is interested in fold changes, Lipid Surveyor will display a bar chart that can rank in order of fold changes in concentration, color-coded based on significance (red = increases, blue = decreases, white = no change). Display options allow you to adjust how your data are organized, from scaling factors and color, as well as adding study notes to your report.

Investigators can dive deeper into their data by individually selecting each bar plot in the visualization. They are then provided data for the selected lipid for both the case and control group in box and whiskers format, p-values associated with the test, and group means. Moreover, investigators can access the public database, Lipid Maps and Human Metabolome Database, for more information about the metabolite. Multiple comparison options are also available during report configuration and provide analyses if the user requires multiple tests.

Overall, Lipid Surveyor provides a simple and efficient way to identify potential biomarkers from thousands of metabolites.

Analyze Lipid Pathways

After the Discovery report provides metabolites of interest, the same group comparisons can be performed in the context of biochemical pathways. Here, investigators have the option of investigating pathway data at the level of fatty acids, sphingolipids, or complex lipids. Parameters are just as customizable as Discovery reports, allowing you to configure study groups, fold-changes or mean differences, and significance levels.

Visualization of pathway maps in Lipid Surveyor is clean and easy to interpret. The resulting map displays each measured metabolite organized by biochemical pathways and color-coded based on magnitude of change in concentration. Like Discovery reports, each node of the pathway can be selected to view a box plot and details for the corresponding lipid. A compositional matrix is also displayed to highlight patterns associated with specific acyl chain types within and across lipid classes.

Filter and Customize Your Lipidomics Report

For further customization, Lipid Surveyor allows investigators to limit which metabolites are displayed in the visualization by adding filters to their data sets. These filters include attributes such as the name, description, and metabolite composition. The filtered attributes limit the Discovery Report display to only show the selected attributes.

Data can be further adjusted by adding signatures to calculate ratios between metabolites and/or groups of metabolites at a species or class level. The investigator can then customize their signature according to the metabolite and desired equation. These signatures are then applied to the Discovery report.

Share Lipidomics Data with Your Collaborators

In addition to being able to download and customize reports for .xlsx formats, Lipid Surveyor provides a simple interface to invite collaborators to view and access study results.

Metabolon’s Lipid Surveyor is comprehensive, efficient, and easy to use. Its data analyses and data visualization capabilities are tailored to your lipidomic study needs and allows figures to be generated that are suitable for data interpretation, presentations, and publications. To see a demonstration of Metabolon’s Lipid Surveyor, take a look at this video.

Shelby Beatty
Shelby is a senior product manager at Metabolon and specializes in developing software products tailored to enhance the client experience and visualization space, enabling organizations to gain invaluable insights in the ever-evolving life science landscape.

Topics

Share this article

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.